During Friday’s current trade, Cowen Group Inc (NASDAQ:COWN)’s shares incline 0.65% to $6.24.
Cowen Group Inc (COWN) declared that Ryan Oatman, CFA has joined Cowen and Company’s Equity Research department as a Director to cover oil & gas exploration & production (E&P) stocks. Mr. Oatman is based in Houston and reports to Robert Fagin, Cowen’s Director of Research.
Mr. Oatman has seven years of experience in Energy sector equity research. He joins Cowen from SunTrust Robinson Humphrey where he was a research analyst, and formerly held similar roles at Canaccord Genuity and FBR Capital Markets.
Mr. Oatman holds a Bachelor of Science degree in Business Administration from Trinity University, and an MBA from the Mays Business School at Texas A&M University. He is also a CFA® charterholder.
Cowen’s energy equity research team comprises nine senior analysts whose coverage spans Energy Portfolio Strategy, Oilfield Services & Equipment, Oil & Gas Exploration & Production, Integrated Oil, Refining, Coal, Energy Transportation, Energy Metals, and Alternative Energy.
Cowen Group, Inc. is a publicly owned asset administration holding company. Through its auxiliaries, the firm provides alternative investment administration, investment banking, research, and sales and trading services for its clients. It manages separate client focused portfolio through its auxiliaries.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)‘s shares gain 0.41% to $7.41, during the current trading session Friday’s, hitting its highest level.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. (PGNX) declared that the European Commission has approved RELISTOR(R) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radio therapeutic product candidate, which is in Phase IIb registration trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
In a mid-morning trade, Lion Biotechnologies Inc (NASDAQ:LBIO)‘s shares surge 1.47% to $10.02.
Lion Biotechnologies Inc (LBIO) declared that the FDA has granted orphan status to the company’s lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma.
The FDA grants orphan status to novel drugs or biologics to treat rare medical diseases or conditions that affect fewer than 200,000 people in the United States. By receiving this designation for LN-144, Lion will be eligible for tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity
Lion Biotechnologies, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient’s immune system to eradicate cancer cells. The company’s lead product comprises LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma.
Paychex, Inc. (NASDAQ:PAYX), during its Friday’s current trading session -0.10% loss and closed at $48.19.
Paychex, Inc. (PAYX) CEO Martin Mucci stated in a phone interview, they believe that this is not the start of a trend but indicative of what they have seen with economic data as it has been inconsistent but still showing overall moderate growth. While the index showed a decline, the trend still signals moderate growth as the reading is over 100.”
A monthly measure of change in small business employment in the U.S., the Paychex/IHS Small Business Jobs Index tracks worker counts. An upward trend represents a strengthening job market, while a downward trend is a sign of a slowdown.
Many regions registered a decline last month. The West-North Central area exhibited the lowest growth rate for the second successive month. The East-North Central region now has the top-ranked position of all the regional indices.
On the state level, Indiana was the one with the highest ranking, demonstrating the best one-month and 12-month growing rates. After having solid total employment growth in April and May as stated by the Bureau of Labor Statistics, Indiana’s ranking climbed to 103.65. Illinois also logged growth, of 0.34%, in May contrast April. With a 102.31 ranking, Michigan saw improvement as its economy transitions to being more technology-based and has call centers, Mucci explained.
Paychex, Inc. provides payroll, human resource, insurance, and benefits outsourcing solutions for small to medium-sized businesses in the United States and Germany. The company offers payroll processing services that comprise the calculation, preparation, and delivery of employee payroll checks; production of internal accounting records and administration reports; preparation of federal, state, and local payroll tax returns; and collection and remittance of clients payroll obligations.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
